| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S11239-015-1306-3 |
| P698 | PubMed publication ID | 26660521 |
| P50 | author | Andreas Zirlik | Q42685004 |
| Christoph Bode | Q60457714 | ||
| P2093 | author name string | Ingo Ahrens | |
| Peter Stachon | |||
| P2860 | cites work | Persistent activation of coagulation mechanism in unstable angina and myocardial infarction | Q72047945 |
| A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction | Q73833294 | ||
| Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin | Q77199911 | ||
| Thrombotic thrombocytopenic purpura after stenting and ticlopidine | Q77367362 | ||
| 2004 ACC/AHA guideline for the management of patients with STEMI: the implications for clinicians | Q81431508 | ||
| Treatment with an oral direct thrombin inhibitor decreases platelet activity but increases markers of inflammation in patients with myocardial infarction | Q83262168 | ||
| A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation) | Q85015607 | ||
| Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial | Q85337405 | ||
| 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines | Q22241919 | ||
| Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial | Q28165358 | ||
| Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials | Q28176219 | ||
| Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial | Q28185738 | ||
| Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit | Q28187822 | ||
| Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation | Q28188284 | ||
| Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients | Q28190844 | ||
| Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial | Q28193437 | ||
| Warfarin, aspirin, or both after myocardial infarction | Q28193836 | ||
| Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary Artery | Q28206536 | ||
| Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty | Q28242220 | ||
| A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group | Q28245560 | ||
| A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators | Q28245573 | ||
| Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials | Q28257083 | ||
| ??? | Q22242895 | ||
| Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty | Q28285343 | ||
| Coronary-artery stents | Q28295059 | ||
| Heart disease and stroke statistics--2014 update: a report from the American Heart Association | Q29547691 | ||
| Ticagrelor versus clopidogrel in patients with acute coronary syndromes | Q29619002 | ||
| Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration | Q29619529 | ||
| Oral rivaroxaban for symptomatic venous thromboembolism | Q29620160 | ||
| A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina | Q33502560 | ||
| A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. | Q33504515 | ||
| Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry | Q34019616 | ||
| Apixaban in patients with atrial fibrillation | Q34163710 | ||
| Apixaban with antiplatelet therapy after acute coronary syndrome | Q34202772 | ||
| Rivaroxaban in patients with a recent acute coronary syndrome | Q34231902 | ||
| Vorapaxar in the secondary prevention of atherothrombotic events | Q34263311 | ||
| New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis | Q34331671 | ||
| Effect of platelet inhibition with cangrelor during PCI on ischemic events | Q34331909 | ||
| A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents | Q34374902 | ||
| Trends in mortality from coronary heart and cerebrovascular diseases in the Americas: 1970-2000 | Q35771589 | ||
| Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial | Q37174455 | ||
| Arterial thrombosis--insidious, unpredictable and deadly | Q37953778 | ||
| Platelets in atherosclerosis and thrombosis | Q38037398 | ||
| Anticoagulation during and after acute coronary syndrome. | Q38171277 | ||
| Antithrombotic treatment for stroke prevention in atrial fibrillation: The Asian agenda | Q38482766 | ||
| D-Dimer is an early diagnostic marker of coronary ischemia in patients with chest pain | Q39545708 | ||
| Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial | Q42687692 | ||
| Intravenous platelet blockade with cangrelor during PCI. | Q43241907 | ||
| Platelet inhibition with cangrelor in patients undergoing PCI. | Q43241909 | ||
| Ticagrelor--is there need for a new player in the antiplatelet-therapy field? | Q43283545 | ||
| Thrombin causes vascular endothelial growth factor expression in vascular smooth muscle cells: role of reactive oxygen species | Q43738102 | ||
| Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes | Q44272454 | ||
| Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. | Q45173221 | ||
| Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. | Q45748252 | ||
| Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. | Q45962608 | ||
| Prasugrel versus clopidogrel in patients with acute coronary syndromes | Q46915044 | ||
| Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis | Q47236623 | ||
| Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials | Q56944618 | ||
| Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial | Q57252716 | ||
| P433 | issue | 2 | |
| P921 | main subject | acute coronary syndrome | Q266018 |
| P1104 | number of pages | 7 | |
| P304 | page(s) | 254-260 | |
| P577 | publication date | 2015-12-12 | |
| P1433 | published in | Journal of Thrombosis and Thrombolysis | Q15766541 |
| P1476 | title | Dual pathway therapy in acute coronary syndrome | |
| P478 | volume | 42 |
Search more.